In phase 3 trial (Il Sole 24 Ore Radiocor) - London, 06 Sep - The UK pharmaceutical group GSK announced positive headline results of a phase III clinical trial evaluating Nucala, a monoclonal antibody that targets interleukin-5 in adults with chronic obstructive pulmonary disease (COPD).

"The preliminary safety results are consistent with the known safety profile of Nucala. Further analysis of these data is ongoing," it said.

COPD affects more than 300 million people globally with up to 40% of patients exhibiting type 2 inflammation characterised by raised blood eosinophil count, that drives exacerbations.

Nucala is currently not indicated for COPD anywhere in the world.

AAA-Web

(RADIOCOR) 06-09-24 11:38:23 (0278) 5 NNNN